Shane Thomas Gleason Sells 5,132 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 5,132 shares of InspireMD stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.46, for a total value of $12,624.72. Following the completion of the sale, the insider directly owned 1,104,601 shares in the company, valued at $2,717,318.46. This represents a 0.46% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total value of $23,005.78.

InspireMD Trading Down 2.9%

Shares of NSPR opened at $1.00 on Friday. InspireMD, Inc. has a twelve month low of $0.97 and a twelve month high of $2.93. The stock’s 50 day moving average is $1.38 and its two-hundred day moving average is $1.66. The firm has a market capitalization of $46.84 million, a PE ratio of -1.33 and a beta of 0.82.

Analysts Set New Price Targets

NSPR has been the topic of a number of analyst reports. Lake Street Capital set a $4.00 price objective on InspireMD in a report on Monday, May 4th. Loop Capital set a $5.00 price target on InspireMD in a research note on Tuesday, February 24th. Maxim Group started coverage on InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 price target on the stock. Finally, Piper Sandler reissued an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, InspireMD has an average rating of “Buy” and an average price target of $4.50.

InspireMD News Roundup

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
• Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
• Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

Institutional Investors Weigh In On InspireMD

Institutional investors have recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in shares of InspireMD during the 4th quarter worth approximately $30,000. Renaissance Technologies LLC purchased a new stake in shares of InspireMD during the 1st quarter worth approximately $29,000. Virtu Financial LLC purchased a new stake in shares of InspireMD during the 4th quarter worth approximately $31,000. Creative Planning purchased a new stake in shares of InspireMD during the 2nd quarter worth approximately $44,000. Finally, Uniting Wealth Partners LLC purchased a new stake in shares of InspireMD during the 3rd quarter worth approximately $51,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.